The advent of next-generation sequencing coupled with multiregion sampling has brought heterogeneity to the forefront of cancer genetics 1,2 . Remarkable examples of this phenomenon have been shown in carcinomas of the breast 3 , kidney 4 , lung 5, 6 , prostate 7-9 , colon 10 , and pancreas 11, 12 and in melanoma 13 . Subclonal populations within a neoplasm are phylogenetically related and can be traced back to a single ancestral population on the basis of their complement of somatic mutations 14 . Such heterogeneity has been extensively documented for more than 50 years and is expected because of the imperfection of DNA replication: every time a normal cell or a cancer cell divides, ~3 new mutations appear 15 .
The advent of next-generation sequencing coupled with multiregion sampling has brought heterogeneity to the forefront of cancer genetics 1, 2 . Remarkable examples of this phenomenon have been shown in carcinomas of the breast 3 , kidney 4 , lung 5, 6 , prostate [7] [8] [9] , colon 10 , and pancreas 11, 12 and in melanoma 13 . Subclonal populations within a neoplasm are phylogenetically related and can be traced back to a single ancestral population on the basis of their complement of somatic mutations 14 . Such heterogeneity has been extensively documented for more than 50 years and is expected because of the imperfection of DNA replication: every time a normal cell or a cancer cell divides, ~3 new mutations appear 15 .
There are at least three types of intratumoral genetic heterogeneity: type 1 involves mutations that distinguish one cell in a primary tumor from another cell of that same primary tumor; type 2 involves mutations that distinguish one cell in a metastatic lesion from another cell in that same metastatic lesion; and type 3 involves mutations within the same primary tumor that distinguish the cell that initiates one metastasis from the cell that initiates another distinct metastasis 16, 17 .
Each of these types of heterogeneity has distinct and important clinical implications. For example, type 1 and type 2 heterogeneity explain in part how primary tumors and metastatic lesions, respectively, develop resistance to therapies that are initially effective [18] [19] [20] . Type 3 heterogeneity determines whether metastases within the same patient with advanced disease will respond to initial interventions. In the current age of targeted therapeutics, this type of heterogeneity has become of paramount importance: unless nearly every metastatic lesion has the same driver gene mutation as the therapy targets, the therapy will fail. Finally, between-individual heterogeneity helps explain why patients with the same histopathological type of tumor respond so differently to the same drug regimen 21 .
Despite the importance of type 3 heterogeneity, there have been few studies that have evaluated this class of heterogeneity through whole-genome sequencing. For example, we could find only four recent publications that have evaluated more than two metastases from any explicitly untreated patient [11] [12] [13] 22 . Although several other studies have evaluated metastatic lesions after therapy, the genetic Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer alterations in such lesions often reflect the mutagenic influences, and strong selective pressures and bottlenecks, associated with therapy, rather than the natural course of disease. Other studies that evaluated somatic copy number alterations (SCNAs), either through karyotyping or other technologies, have been published, but in general the changes evaluated can not be interpreted with respect to driver genes 23, 24 .
In the current study, we evaluated type 3 heterogeneity in pancreatic ductal adenocarcinomas (PDACs). PDAC is notorious for presenting as metastatic disease at diagnosis and has a dismal 5-year survival rate (7%); it is projected to become the third most common cause of cancer death by the end of 2017 (ref. 25) .
RESULTS

Patient and sample cohort
We implemented strict clinical and technical criteria to identify the optimal patients for study from more than 150 autopsied patients for whom tissues were available from a rapid medical donation program (Supplementary Table 1 ) 26 . First, we exclusively used samples from untreated patients for the reasons described above. Second, patients with unusual biological variants of PDAC were also excluded because these variants differ from the more common ductal adenocarcinomas in their pathogenesis, driver gene alterations [27] [28] [29] , and clinical outcomes 30, 31 . Third, we required that all patients have stage IV disease, that at least two metastases be available for study, and that the metastases available from each patient accurately represent the disease burden at autopsy (Supplementary Table 1) .
On the basis of these criteria, we identified four patients for detailed evaluation. Histological sections were prepared from snap-frozen samples of the primary tumors and metastases from these four patients to estimate tumor cellularity and tissue quality. Samples with low neoplastic cellularity were excluded, as were any tissue samples with confluent necrosis that would yield low-quality genomic DNA (Online Methods). The remaining samples were macrodissected to remove as much normal tissue as possible before genomic DNA was purified. A similar approach was previously described 11 , but in that study only a single metastasis from each patient was evaluated by genome-wide Sanger sequencing, precluding quantification of heterogeneity and limiting the ability to discern evolutionary relationships among metastatic lesions. In all, we identified 26 metastatic lesions suitable for study, as well as samples of the primary tumor and normal tissues, from these four patients (Supplementary Tables 2 and 3) .
Genomic DNA from 39 samples (26 metastatic lesions, up to 3 distinct regions of each primary tumor, and normal tissues) were evaluated by 60× whole-genome sequencing using an Illumina HiSeq 2000 platform 32 (Fig. 1a,b) . Notably, all metastases were discrete tumors by both gross examination at autopsy and histological review, ensuring that each metastasis represented an independent neoplasm at the corresponding location (Fig. 1c) . The metastases were derived from diverse organs, including the liver, lung, peritoneum, and lymph nodes, all typical secondary sites of pancreatic cancer 33 . DNA from the normal tissues of each patient was used to facilitate identification of somatic variants.
Identification of somatic and driver gene mutations
The raw data were filtered for mapping quality and aligned to the hg19 human reference genome, indicating an average coverage of 68× with 97.6% of bases covered by >10× (Supplementary Table 4 ). As KRAS is mutated in PDAC at a high frequency, we used the mutant allele fraction (MAF) of KRAS as an independent metric of the neoplastic cellularity of our samples. This metric is particularly important given the high non-neoplastic stromal content of many PDACs 34 .
It is well known that massively parallel sequencing can yield many artifacts 32, 35 . Moreover, varying estimates of tumor content across samples within an individual complicate the identification of parsimony-informative mutations for inferring the genetic relationships among different lesions. We therefore employed filtering criteria to limit potential sequencing artifacts and enrich for true somatic mutations within this sequencing data set (Online Methods), resulting in a list of 3,811 distinct variants among the samples. The vast majority of these mutations were shared by all samples from the same patient ( Fig. 2a and Supplementary Fig. 1 ). Private (unique) somatic mutations within each primary tumor sample and different metastases were nonetheless identified, as expected. KRAS mutations were identified in every sample from all four patients. Mutations in other driver genes, for example, TP53, SMAD4, ARID1A, and ATM 36, 37 , were also identified in all samples from each patient in which any lesion from that patient contained a mutation (Supplementary Table 5) .
Homozygous deletions or amplifications that target critical driver genes are not detectable by sequencing when tumor samples contain contaminating non-neoplastic cells. This is of particular importance for tumor-suppressor genes in PDAC, for which homozygous deletion is a common mechanism of inactivation 21 . To address this issue, we first immunolabeled each sequenced tissue sample for the proteins From innermost to outermost, the rings correspond to samples, LiM1, LiM2, NoM1, and NoM2.
A r t i c l e s encoded by CDKN2A, TP53, and SMAD4, all of which are frequently inactivated in PDAC. Loss of expression for CDKN2A was noted in the primary tumors of all four patients, suggesting that a homozygous deletion or epigenetic silencing was responsible for the inactivation of this tumor-suppressor gene 38 . Notably, every metastatic lesion for each of these four patients exhibited loss of expression of CDKN2A (Fig. 2b) . Similarly, loss of expression of TP53 in Pam01 and Pam03 was identified in all samples from these two patients, who were the two not found to exhibit mutations detectable by whole-genome sequencing in the corresponding gene. Of interest, known homozygous deletions of CDKN2A and TP53 have previously been reported in a cell line derived from Pam01 (PA03C in ref. 36) . Missense mutations identified in TP53 for Pam02 (p.Leu344Pro), in ARID1A for Pam02 (p.Tyr579*), and in SMAD4 for Pam04 (p.Asp351Gly) corresponded to immunolabeling patterns for the encoded proteins concordant with the predicted effects of these mutations (Supplementary Fig. 2 ), and these labeling patterns were uniformly present in all samples from each patient studied.
In conjunction with the sequencing and immunohistochemistry results, we reviewed the predicted SCNAs in each sample to further assess genetic amplifications or deletions. We observed many common, partially shared, or private copy number variants (CNVs) among the samples in each case, most of which encompassed tens to thousands of genes ( Fig. 2c, Supplementary Figs. 3-7 , and Supplementary Table 6 ). In these regions, distinguishing an evolutionarily selected low-level copy number event from stochastic aneuploidy is challenging 23, 24, 39 . However, some patterns emerged. We noted that the higher the fold of amplification, the fewer the genes that were included in that amplicon. This led to the identification of candidate somatic target genes with a reasonable level of certainty. Examples of such focal gains were GATA6 and MYC in Pam01 and KRAS in Pam02. These gains were present in every sample in each patient (Supplementary Table 7 ). Copy number losses of tumor-suppressor genes such as ARID1A, CDKN2A, ROBO1, SMAD4, SMARCA2, and TP53 were also identified. Losses followed a similar trend in that, the fewer the genes involved in the region of loss, the more likely the region was to involve an undisputed PDAC driver gene, for example, CDKN2A in Pam04 (Supplementary Table 7 ) 21 . In some instances, losses appeared to be heterogeneous across different samples from the same patient, for example, loss of SMAD4 in Pam01 and loss of CDKN2A in Pam02. However, as discussed above, immunohistological evaluation of expression from these two genes showed complete concordance in all sequenced samples for each patient. These data suggest that, in samples with relatively low levels of neoplastic cells, immunohistological analysis can add clarity 
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to the interpretation of 'negative' sequencing data, that is, where homozygous losses are not easily identified. We also identified putative structural variants for each case ( Supplementary Fig. 8 and Supplementary Tables 8-11 ). These included 3,516 break ends (average of 101 per sample), 2,763 inversions (average of 79 per sample), 1,291 tandem duplications (average of 37 per sample), and 48 insertions (average of 2 per sample). Of these, a minor fraction involved known or candidate driver genes in PDAC, most of which were already identified by immunolabeling or copy number analysis. However, one liver metastasis each in patients Pam02 and Pam03 exhibited several unique inversions, the relevance of which is not clear (Supplementary Fig. 8 ). Similarly, it is at present difficult to determine the importance, if any, of structural variations not adjacent to driver genes 12, 21, 27 .
Quantifying type 3 heterogeneity
To examine the extent of type 3 heterogeneity in a quantitative fashion, we assessed the differences in single-base substitutions among the founding cells of metastases with respect to a null model of genetic heterogeneity. The classical null model, 'genetic identity' , assumes that all tumor cells exhibit exactly the same genetic mutations. However, as the tumors we evaluated are composed of exponentially growing populations of billions of cells, a null model of genetic identity seems unsuitable given the known imperfection of DNA replication. We therefore employed the 'expected genetic differences in normal tissues' as an appropriate null model to assess genetic heterogeneity.
To ensure that only the highest quality data were used for these analyses, we employed a targeted sequencing approach based on custom-designed capture probes comprising the ~100-nt sequences surrounding the 3,811 variants of interest. We performed targeted sequencing on the original 39 samples used for whole-genome sequencing as well as 4 additional metastatic lesions from the same four patients. In total, we identified 614 bona fide mutations in the metastases through this targeted approach (Online Methods and  Supplementary Tables 2, 3 , and 12). This highly curated list of 614 mutations included variants in passenger genes as well as in the drivers of pancreatic cancer described above, with a median distinct depth of sequencing of 255× (Supplementary Table 4) .
We investigated two measures of genetic heterogeneity: genetic distance ('divergence') 40 and Jaccard similarity coefficient. Genetic distance is defined by the total number of non-shared genetic variants present in two samples. The Jaccard similarity coefficient is defined as the ratio of shared variants to all (shared plus discordant) variants for two samples ( Table 1 and Supplementary Table 13 ). For example, two metastatic lesions from the same patient sharing zero mutations would have a Jaccard similarity coefficient of 0, while two lesions with completely identical mutations would have a coefficient of 1. The similarity coefficient is indifferent to the number of base pairs sequenced, which differed considerably for some of the samples (Supplementary Table 4) .
Because mutations present in the founder cells of each metastasis are by definition present in all the cells of the metastasis once the founder cells clonally expand, all mutations present in the founder cells can be detected by bulk sequencing. The total measured heterogeneity among metastases thus reflects the heterogeneity of the individual founder cells (type 3 heterogeneity) plus additional heterogeneity resulting from high-frequency mutations subsequently acquired during the growth of the metastasis (type 2 heterogeneity). The measured Jaccard similarity indices therefore represent a lower bound on the similarity between founder cells of the metastases. In contrast, standard bulk sequencing of DNA from normal tissues is not appropriate for comparisons, as this sequencing would not identify differences among individual cells 41, 42 . Likewise, singlecell sequencing is currently too error prone to allow comparisons to rely on the data from a single cell, and identification of the same mutation in more than one cell is generally required for accuracy 14 . Given these challenges, we employed an alternative approach in which the somatic evolution of most types of normal tissues was modeled. The models incorporate stochastic evolutionary processes with differing renewal patterns ( Fig. 3a and Supplementary Note) . In the simplest case (scenario 1), we modeled an organ that grows via a pure birth branching process to a certain number of cells (n cell ), with no further cell divisions (mimicking neuronal cells, for example). For n cell = 10 10 , the expected Jaccard similarity coefficient is ~0.03 for two randomly chosen cells from the tissue. For a more complex case (scenario 2), we derived the similarity coefficient for an organ with a certain number of crypt cells (n crypt ), where each cell founds a single isolated compartment (such as an intestinal crypt) that continuously replenishes itself, with no mixing or replacement (mimicking intestinal epithelial cells). In this case, the coefficient is less than 0.04 in two randomly chosen cells from the tissue (assuming n crypt = 10 7 cells). Finally, we considered a tissue with a certain number of stem cells (n stem ) that not only continuously divide but also exhibit high levels of replacement and mixing (mimicking hematopoietic cells; scenario 3). For this final scenario, the Jaccard similarity coefficient is <0.2 for relevant time scales and cell population sizes (>10 4 cells) and further diminishes as the population size of an organ increases. s u e P a n c r e a t ic c a n c e r Jaccard similarity coefficient A r t i c l e s 
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Thus, for two randomly chosen cells from healthy tissues of various renewal types, the expected similarity coefficient ranges from near 0 to no greater than ~0.2 ( Fig. 3b and Supplementary Note). These theoretical predictions were recently experimentally corroborated by Blokzijl et al., who measured the genetic heterogeneity in organs from 13 healthy individuals by sequencing organoid cultures derived from 38 individual cells 42 . Using their published mutation data, we found that the mean Jaccard similarity coefficient for two cells from the same colon was 0.075, from the same liver was 0.033, and from the same small intestine was 0.011 ( Fig. 3b and Supplementary Table 14) . Next, we calculated the Jaccard similarity coefficients for the various pairs of metastases on the basis of their validated mutations. The coefficients averaged 0.89 (Fig. 3b and Table 1 ). The Jaccard similarity coefficient of any metastatic lesion relative to any other metastatic lesion from the same patient was far higher (minimum of 0.67) than that for any modeled normal tissue. Thus, these data suggest that the founder cells that seeded these metastatic lesions were more highly related than expected for any two randomly chosen cells from a single normal tissue (P < 0.0003, Welch's t test). This finding remained valid when using the stringently filtered whole-genome data set or when excluding founder mutations (P < 0.0027, Welch's t test; Fig. 3c and Supplementary Tables 13 and 15) .
Pairwise genetic distances 40 -defined as the total number of nonshared genetic mutations across the entire exome for two cells-were also calculated for the metastases on the basis of their validated mutations. We found a maximum of 44, 10, 13, and 36 mutations separating metastases in Pam01, Pam02, Pam03, and Pam04, respectively (Online Methods and Supplementary Tables 16 and 17 ). All measured distances were considerably less than expected for two randomly chosen cells from a normal tissue with dividing cells (scenario 2).
Finally, to determine whether our findings could be generalized to other patients, we performed 150× whole-exome sequencing on ten primary and metastatic samples from two additional untreated patients who were accrued during the course of this work ( Supplementary  Fig. 9 and Supplementary Table 18 ). We again found that the vast majority of variants were shared by all samples for each patient. There was complete uniformity of alterations in known driver genes at the single-nucleotide level in all spatially distinct primary tumor samples and metastases from each patient. The average of the Jaccard similarity coefficients was 0.73, again indicating a high level of genetic similarity for both driver and passenger genes among the founder cells of the metastases.
Phylogenetic analyses of metastases and primary tumor sections
To determine whether the high similarity among metastasis founder cells was consistent with the evolution of these tumors, we first performed targeted sequencing on a total of 59 spatially distinct regions of the four primary tumors from which the metastases emerged (Supplementary Table 2 ). Because the high similarity coefficients of metastases complicated evolutionary reconstructions, we used Treeomics 43 to derive phylogenetic trees (Fig. 4a,b and Supplementary  Figs. 10-14 and Supplementary Note). Details of this approach are provided in the Online Methods. In general, the trees were consistent with the expected generation of metastases from primary tumors. In patients Pam02 and Pam03, we found that metastases in the liver were more likely to be derived from different subclones in the primary tumor than from each other (Fig. 4a,b and Supplementary Fig. 10 ). This suggested that there were a variety of subclones in the primary tumors that independently gave rise to highly related but independent metastatic lesions; no single subclone within the primary tumors gave rise to all, or even most, of the metastases (Fig. 4a,b and Supplementary Figs. 10a,b and 11a,b) . Notably, all of the driver genes identified in the metastases were also identified in all regions of the primary tumors. Phylogenetic analysis also showed that there were no spatially definable regions based on multiregion sampling and mapping before sequencing among the subclones in the primary tumor, nor could the locations of such regions be predicted on the basis of their relatedness 44 (Fig. 4c,d and Supplementary Figs. 10c,d  and 11c,d) . For example, some adjacent sections were observed to be genetically distant (for example, PT7 and PT14 in Fig. 4d) . Conversely, tumor sections that were separated by several centimeters were often more genetically similar (for example, PT2 and PT3 in Fig. 4d ). These observations can be explained by differential rates of clonal expansion or clonal migration, among other possibilities 44, 45 . We note that the high genetic similarity with no or only a few detected differences between some samples prevented conclusive statements about the evolutionary relationships among these samples (reflected by the low bootstrapping values in Supplementary Fig. 11 ). We found no evidence to support cross-seeding of metastatic lesions by one another, as expected from a recent study of murine pancreatic cancers 46 .
DISCUSSION
In sum, our data indicate that mutations in known driver genes in the metastases of individual patients with PDAC are remarkably uniform. This observation is encouraging with respect to the potential to treat patients with advanced cancer using therapeutic agents targeted to these mutations. Whether such uniformity among driver gene mutations in different lesions is found in other tumor types in general is not yet known because, as noted above, so few metastases from untreated patients with other cancer types have been analyzed using wholegenome sequencing data. However, available evidence indicates that this uniformity is observed in endometrial 47 , prostate 9 , and lung 6 cancers but perhaps not in kidney cancers 4, 48 .
One caveat of our study is that we did not assess the potential type 3 heterogeneity of epigenetic changes among metastases 49 . Another potential limitation is that the effects of CNVs on genetic drivers in PDAC are difficult to determine, even following careful dissection, because of the substantial amounts of non-neoplastic cells that remain in the purified DNA. To partially circumvent this challenge, we used immunohistochemical methods to evaluate metastatic lesions for inactivation of the most commonly altered tumor-suppressor genes (Supplementary Fig. 2 ). We were thus able to evaluate the effects of likely epigenetic silencing and certain types of CNVs in these genes. We indeed identified alterations of these genes, and, as with the sequencing data, there was complete uniformity among the patterns observed in the metastatic lesions from any individual patient. A third limitation is that we could only evaluate known driver genes, identified through previous genome-wide studies of more than 500 PDACs. It is possible that additional driver genes, not yet discovered, could exhibit type 3 heterogeneity in the tumors we examined. Similarly, it is currently challenging to reliably assign specific driver genes in regions of copy number gain or loss that extend over large regions of the chromosomes 23, 24 . Heterogeneity of putative or as yet undiscovered genes or combinations of genes in these regions would not be evident in our analysis.
The absence of type 3 heterogeneity among PDAC driver gene mutations contrasts with the extent of type 3 heterogeneity in passenger mutations in the same tumors. Indeed, we observed many genetic differences among various metastases from the same patients. Such heterogeneity is consistent with a large number of other studies, beginning decades ago, that demonstrate genetic heterogeneity among tumor cells. The older, classical studies focused on karyotypic changes, as no driverA r t i c l e s gene mutations were known and the technology to detect them had not yet been invented. The growth dynamics after clonal expansion of some cancers seem to be dominated by neutral evolution 50 , resulting in considerable intratumoral heterogeneity of passenger mutations 51 . Our null model builds on these findings and represents a new way to contextualize intratumoral heterogeneity in a meaningful fashion. Moreover, our mathematical framework can also be used to interpret the genetic heterogeneity in other tissues sequenced in the future and thereby help to understand their clonal architecture.
The comparisons of the Jaccard similarity coefficients among metastases and those expected and measured in normal tissues, and the phylogenetic evaluations of a large number of spatially distinct lesions within primary tumors, lead to additional insights into PDAC tumor evolution. Collectively, these analyses suggest that metastasis follows at least one major selective sweep that affects the majority of cells within the primary tumor that harbor the final genetic event(s) required for their establishment in distant organs.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
Selection of patient autopsies. The four patients and their respective tissues originated from the Gastrointestinal Cancer Rapid Medical Donation program, a collection of over 150 autopsy cases. Informed consent was obtained from all subjects. This program has been described previously and was deemed in accordance with the Health Insurance Portability and Accountability Act and approved by the Johns Hopkins institutional review board 26 .
Processing of tissue samples. Once the body cavity was opened using standard autopsy techniques, the entire pancreas and primary tumor were removed along with each grossly identified metastasis. All tissues were immediately flash frozen in liquid nitrogen and stored at −80 °C. Each primary tumor was serially sliced into 0.5-cm slices followed by sectioning of each slice into 1 × 1 cm tissue samples, as described previously. One-half of each tissue sample was fixed in 10% buffered formalin while the remaining tissue was preserved at −80 °C. Each metastasis was macrodissected to remove surrounding nonneoplastic tissue. Each frozen primary tumor sample was embedded and frozen in Tissue-Tek OCT for sectioning using a Leica Cryostat. For each tissue sample, a 5-µm section was taken to create a hematoxylin and eosin slide to visualize neoplastic cellularity using a microscope. A different set of lesions from patient Pam01 were evaluated in ref. 11 ; the three other patients described in this paper had not been evaluated previously. We estimated that the neoplastic cellularity was >50% for Pam01, Pam02, and Pam03 and >20% for Pam04.
DNA extraction and quantification. Genomic DNA was extracted from each tissue piece using standard phenol-chloroform extraction followed by precipitation in ethanol. The genomic DNA was quantified by LINE assay (i.e., counting long interspersed elements (LINEs) using real-time PCR), a particularly sensitive method for calculating genomic DNA concentration for wholegenome sequencing. The LINE primers are listed in Supplementary Table 19 . The real-time PCR protocol was 50 °C for 2 min, 95 °C for 2 min, 40 cycles of 94 °C for 10 s, 58 °C for 15 s, and 70 °C for 30 s, 95 °C for 15 s, and 60 °C for 30 s. The PCR reactions were carried out using Platinum SYBR Green qPCR Mastermix (Invitrogen). Only tissue samples that were confirmed to be of high quality and suitable concentration (>25 ng/µl of amplifiable genomic DNA) were used for whole-genome or whole-exome sequencing.
Whole-genome sequencing and alignment. For whole-genome sequencing, several metastases were chosen from all four cases along with three distinct sections of the primary tumor from three of the four cases for a total of 35 samples. Whole-genome sequencing was performed on an Illumina HiSeq 2000 platform for a target coverage of 60×. Following the completion of sequencing, the data were retrieved and analyzed in silico to determine overall coverage and read quality. Reads were aligned to the hg19 human reference genome. All low-quality, poorly aligned, or dbSNP-containing reads were removed from further analysis.
To identify potential drivers, we queried the variant lists for mutations through a combination of previously identified oncogenes and tumor suppressors. This list included driver genes identified via a ratiometric approach 16 , documented hotspots 28 , and significantly mutated genes identified in recent sequencing studies of pancreatic cancer 27, 28, 36, 37, 52 . For a variant to be considered, it had to be non-silent and occur within two or more of the following types of genes: (i) an oncogene or tumor-suppressor gene 16 , (ii) a significantly mutated or known driver gene or pathway in PDAC 21, 27, 36, 37, 52 , (iii) a key gene or pathway in PDAC 21 , or (iv) a gene known to have bona fide hotspots 28 (Supplementary Table 12 ).
Whole-exome sequencing, alignment, and filtering. For whole-exome sequencing, the data processing pipeline for detecting variants in Illumina HiSeq data was as follows. First, the FASTQ files were processed to remove any adaptor sequences at the end of the reads using Cutadapt (v1.6). The files were then mapped using the BWA mapper (bwa mem v0.7.12). After mapping, the SAM files were sorted and read group tags were added using Picard tools. After sorting in coordinate order, the BAM files were processed with Picard MarkDuplicates. The marked BAM files were then processed using GATK (v 3.2) according to best practices for tumor-normal pairs. They were first realigned using IndelRealigner, and the base quality values were then recalibrated with BaseQRecalibrator. Somatic variants were then called in the processed BAM files using MuTect (v1.1.7).
To identify somatic variants for tumor samples from Pam13 and Pam16, the criteria we used were as follows. Each variant had to have been observed in ≥3 reads; each mutation had to have been observed in ≥1 read in both directions (i.e., 5′ to 3′ and 3′ to 5′, relative to the reference genome); each mutation had to not have been observed in >2% of the reads of the matched normal sample; the minimum MAF was 5%; and the matched normal sample must have had at least 10 reads in total. With manual inspection of the raw data, this approach resulted in a total of 330 putative mutations for phylogenetic analysis. Driver gene mutations were analyzed using the same approach from the whole-genome sequencing data (Supplementary Table 18 ).
Filtering of whole-genome sequencing data and visualization. Wholegenome sequencing generated a large list of potential mutations, even after conventional filtering based on quality scores. A total of 54,433 discrete coding and noncoding somatic mutations were identified, with an average of 4,759 mutations per sample. We assessed these data with the goal of identifying bona fide mutations and eliminating sequence artifacts. The criteria used to achieve this goal were relaxed in comparison to what we have previously used 16, 53 given the variation in neoplastic cell content among the samples (Supplementary Table 3 ) and our desire to identify somatic mutations (i.e., high sensitivity, intermediate specificity). Furthermore, we planned on experimentally validating each mutation and could thereby tolerate a higher fraction of false positives in this analysis. The criteria we used were as follows. Each mutation had to have been observed in >3 reads (with a read defined as the output from one cluster on the Illumina instrument); each mutation had to have been observed in ≥1 read in both directions (i.e., 5′ to 3′ and 3′ to 5′, relative to the reference genome); each mutation had to not have been observed in any reads of the matched normal sample; and the minimum MAF was 10% in samples from patients Pam01, Pam02, and Pam03 and 5% in samples from patient Pam04 given the lower neoplastic cell content of the samples from patient Pam04 (Supplementary Table 3 ). This analysis yielded a total of 3,811 potential mutations for subsequent validation.
Targeted sequencing design and validation. Strict filtering of the wholegenome sequencing data resulted in a highly conservative and confident list of potential mutations that defined the clonal mutation profile for each tumor sample. This list of 3,811 variants was used to design a targeted sequencing effort that incorporated the mutation position ±50 bp. Additionally, we aimed to increase the sensitivity of mutation detection by increasing our target coverage to >200×. To do this, we implemented an Illumina-chip-based targeted sequencing approach. Once sequencing was completed, the raw data were aligned and processed as described for the whole-genome sequencing data. To filter the chip data for high-quality mutations, we removed those that had MAF greater than 2%, had no distinct coverage in the corresponding normal sample, or did not pass manual review in the whole-genome sequencing raw data.
Evolutionary analysis methods.
We leveraged the passenger mutations identified in the whole-genome sequencing of each sample to infer an overall false positive rate for the mutations of 0.23%, given that two independent cancers were extremely unlikely to harbor identical passenger mutations. In detail, we counted the number of reads in the targeted sequencing data reporting a passenger mutation in samples from different patients where the mutation was originally identified in the whole-genome sequencing data. The counted number of reads divided by the total number of reads at these positions was used to estimate the false positive rate. We then used a statistical approach, based on mutant read counts and overall coverage of the targeted sequencing data, to determine whether a variant was present, absent, or unknown in each matched sample by calculating a P value for each variant via a binomial distribution. The null hypothesis was that the mutation was absent. We used the step-up method of Benjamini and Hochberg 54 to control for an average FDR of 5% in the combined set of P values from all samples in a patient. Variants with a rejected null hypothesis were labeled as present. The remaining variants (that failed to reject the null hypothesis) were labeled as absent if their coverage was ≥100× and were otherwise labeled as unknown. Variants determined to be present or absent were then used for phylogenetic analysis. However, we excluded tumor samples with median coverage <100× or median-MAF <5% based on targeted sequencing data.
On the basis of validation and filtering of the variants above that underwent targeted resequencing, we derived phylogenies for each patient. The evolutionary trees were 'rooted' at the matched normal sample for each patient, and leaves were formed by the tumor samples (i.e., distinct parts of primary tumors or distinct metastatic lesions). We applied Treeomics, a tool to reconstruct the phylogeny of a cancer using commonly available sequencing technologies 43 . Treeomics employs a uniquely designed Bayesian inference model to account for error-prone sequencing and varying, low neoplastic cell content to calculate the probability that a specific variant is present or absent in each sequenced lesion. On the basis of mixed-integer linear programming, we obtained phylogenies consistent with the biological processes underlying cancer evolution [55] [56] [57] . In the case of many samples (>12) per patient, we used a heuristic to efficiently explore the solution space, and the acquisition of some variants therefore remained ambiguous. For consistency, we assumed a sequencing error rate of 0.5% across all subjects in the phylogenetic analysis.
We found that the large majority of mutations were acquired before genetic divergence in our samples. The low extent of genetic heterogeneity among the samples resulted in relatively 'low' support (indicated by rather low bootstrapping values) for branching events, a difficulty also observed in sequencing studies of incipient or recently diverged species. Across the four patients, the number of acquired mutations ranged from 92-219. Because we obtained ~50 samples per subject, it seems unlikely that biologically relevant tumor subclones would fail to be detected in all samples of a given patient. However, we cannot completely exclude this possibility.
Immunohistochemistry for driver gene expression. Although we restricted our evolutionary analyses to point mutations, we sought to determine the extent to which alternative genetic or epigenetic events might be affecting common PDAC drivers. Briefly, slides bearing tissue were heated at 60 °C for 10 min, deparaffinized, and rehydrated using an ethanol gradient to water. Slides were exposed to Dako Target Retrieval solution for 25 min in steam conditions and allowed to cool for 30 min. Tissue slides were subsequently washed. Each antibody was diluted according to the manufacturer's protocol in Dako antibody diluent. Slides were treated with antibody dilution for 1 h at room temperature and subsequently washed. Dako Labeled Polymer HRP was used as a secondary antibody, exposed to slides for 10 min followed by slide washing. Each slide was treated with 3,3′-diaminobenzidine (DAB) for 2.5 min, washed in deionized water, and then stained with hematoxylin and washed. Tissue slides were subsequently dehydrated through an increasing ethanol gradient, dried, and visualized. We implemented immunohistochemistry for CDKN2A (Ventana, 725-4713), TP53 (Dako, M700101-2), SMAD4 (Santa Cruz Biotechnology, sc-7966), and ARID1A (Santa Cruz Biotechnology, sc-32761) on matched tumor sections from each of the four cases ( Supplementary  Fig. 2) . We also used this approach to determine expression patterns in the primary tumor and metastasis samples for Pam01.
Analyses of SCNAs and B-allele frequency. For tumors that underwent whole-genome sequencing, we used the Control-FREEC package to call CNVs. All read counts in BAM files for tumor samples were first corrected for read counts in the matched normal BAM file and then normalized for GC content bias given the hg19 reference genome 58 . Ploidy was assumed to be 2 for all cases. Contamination by normal cells was estimated by targeted resequencing for each individual tumor sample. Window and step sizes were set to 50,000 bp and 10,000 bp, respectively. The threshold for segmentation of the normalized profiles was set to 0.6, lower than the default, to obtain more predicted CNV segments. We finally selected significant CNVs that passed both Wilcoxon and Kolmogorov-Smirnov tests (P < 0.05) 58, 59 .
Additionally, more than 3,000 SNPs were used to estimate B-allele frequencies at the chromosomal level in two cases, Pam01 and Pam02. Major copy number alterations and loss-of-heterozygosity events were observable in all primary tumor sections and metastases (Supplementary Figs. 2-5) .
In identifying putative driver genes involved in SCNAs (Supplementary  Table 7) , the SCNA had to be an amplification with copy number ≥5 or a deletion with copy number = 0 in at least one tumor sample within each case, involving (i) an oncogene or tumor-suppressor gene 16 or (ii) a key gene or pathway in PDAC 21 . In identifying recurrent chromosomal losses or gains, at least one SCNA had to be an amplification with copy number ≥5 or a deletion with copy number = 0 in at least one tumor sample within each case while occurring in a recurrently altered chromosome band in PDAC 27 .
Structural variant analysis.
To identify structural variants in the wholegenome sequencing data, the GROUPER module in CASAVA (version 1.1a1) was used with standard settings. Structural variants present in the patientmatched normal sample were filtered from subsequent analysis. Driver genes were identified using the same references as for the SCNAs. 
